| This week's sponsor is FierceBiotech’s Drug Development Forum. | | FierceBiotech’s Drug Development Forum – September 19-21, 2016 Join leading biotech professionals in the first-ever Drug Development Forum in Boston. Discover the latest trends, challenges, and innovations in the biotech industry. Sign up by July 29, 2016 and save $200 on registration.
Register now |
Top Stories Tuesday, July 12, 2016 Flagship Ventures hopes to create a new immune-microbiome company that will have a candidate in the clinic next year--through the combination of a pair of its existing portfolio companies. The resulting company has nabbed $40 million thus far and is moving forward with a combined employee staff of 42. Tuesday, July 12, 2016 New York preclinical cancer biotech Sapience Therapeutics has managed to gain a $22.5 million pot of cash in its first funding round as it looks to progress with its lead candidate ST-36. Tuesday, July 12, 2016 A year after the small, early-stage Californian IBD biotech Protagonist Therapeutics managed to raise $40 million, the company is now seeking to go public with a $75 million offering. Tuesday, July 12, 2016 Shire has been given a key U.S. approval for its new eye disease drug lifitegrast nearly a year after it was rejected by the FDA, and can now look to make good on its expected blockbuster sales. Tuesday, July 12, 2016 In spite of its positive spin on what at best was a mixed bag of results, CytRx could not stop the tanking of its shares last night after it posted new data from its key Phase III cancer trial of its last remaining product. Tuesday, July 12, 2016 Bayer has been testing out its relationship with X-Chem since 2012. Now, after already having licensed two programs from it, the pharma has upped the ante with a bigger discovery deal. Tuesday, July 12, 2016 Cell Medica has bought Delenex, a Swiss biotech that spun out of ESBATech as part of its $589 million takeover by Novartis’ Alcon. The deal gives Cell Medica single chain FV fragment technology that will serve as the targeting system for the chimeric antigen receptor (CAR) therapies it is codeveloping with Baylor College of Medicine. | | | Swiss biotech NLS Pharma Group has been given an orphan drug designation by the FDA for its drug Mazindol in the treatment of narcolepsy. Release Lyon, France-based oncology biotech BliNK has closed an extra €1.65 million on its funding round, bringing its total Series A to €5.65 million. Statement Sernova and JDRF have announced new funding of a joint research collaboration in severe Type 1 diabetes. Release Seres Therapeutics and Emulate have signed a pact to develop new microbiome meds for inflammatory bowel disease. Statement | |
|
Resources Sponsored by: SDC Interested in intended use validation of SaaS-based EDC systems? Prefer to discuss rescue study strategies and considerations? How about understanding statistical power for non-statisticians? Vote for your favorite webinar topic to be presented by SDC at DIA on June 28, 2016, 12pm EDT. Cast Your Vote Here to receive your exclusive event invitation and a recording of the webinar after the event. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. FierceBiotech Drug Development Forum September 19-21, 2016 | Boston, MA Immunotherapy: Mapping the future July 28, 2016 | Foster City, CA BioImmersion: In Depth Biotech for the Non-Scientist October 5-7, 2016 | Chicago, IL Drug Development Boot CampTM 2016 November 16-17, 2016 | Boston, MA Characterization of Animal Models for Alzheimer’s disease: Webinar Presented by Charles River July 19, 2016 Master of Science in Bioinformatics at Northeastern University Fall 2016, Spring 2017 Courses BIOSPAIN 2016 September 28-30, 2016 | Bilbao, Basque Country, Spain |
